发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Adverse effects of ferroptotic therapy: mechanisms and management. 铁剂治疗的不良反应：机制与处理。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-05-01 Epub Date: 2024-01-20 DOI: 10.1016/j.trecan.2024.01.002
Jiao Liu, Rui Kang, Daolin Tang
{"title":"Adverse effects of ferroptotic therapy: mechanisms and management.","authors":"Jiao Liu, Rui Kang, Daolin Tang","doi":"10.1016/j.trecan.2024.01.002","DOIUrl":"10.1016/j.trecan.2024.01.002","url":null,"abstract":"<p><p>Ferroptosis, a nonapoptotic form of cell death characterized by iron accumulation and uncontrolled lipid peroxidation, holds promise as a therapeutic approach in cancer treatment, alongside established modalities, such as chemotherapy, immunotherapy, and radiotherapy. However, recent research has raised concerns about its side effects, including damage to immune cells, hematopoietic stem cells, liver, and kidneys, the development of cachexia, and the risk of secondary tumor formation. In this review, we provide an overview of these emerging findings, with a specific emphasis on elucidating the underlying mechanisms, and underscore the critical significance of effectively managing side effects associated with targeted ferroptosis-based therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"417-429"},"PeriodicalIF":14.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139513750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fusion genes in pancreatic tumors. 胰腺肿瘤中的融合基因。
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-05-01 Epub Date: 2024-02-19 DOI: 10.1016/j.trecan.2024.01.009
Anastasios Gkountakos, Aatur D Singhi, C Benedikt Westphalen, Aldo Scarpa, Claudio Luchini
{"title":"Fusion genes in pancreatic tumors.","authors":"Anastasios Gkountakos, Aatur D Singhi, C Benedikt Westphalen, Aldo Scarpa, Claudio Luchini","doi":"10.1016/j.trecan.2024.01.009","DOIUrl":"10.1016/j.trecan.2024.01.009","url":null,"abstract":"<p><p>Gene fusions and rearrangements play a crucial role in tumor biology. They are rare events typically detected in KRAS wild-type (WT) pancreatic tumors. Their identification can inform clinical management by enabling precision oncology, as fusions involving BRAF, FGFR2, RET, NTRK, NRG1, and ALK represent actionable targets in KRAS-WT cancers, and serve diagnostic purposes since fusions involving PRKACA/B represent the diagnostic hallmark of intraductal oncocytic papillary neoplasms (IOPNs). Although they are rare, the therapeutic and diagnostic importance of these genomic events should not be underestimated, highlighting the need for quality-ensured molecular diagnostics in the management of cancer. Herein we review the existing literature on the role of fusion genes in pancreatic tumors and their clinical potential as effective biomarkers and therapeutic targets.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"430-443"},"PeriodicalIF":18.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineered bacterial therapeutics for detecting and treating CRC 用于检测和治疗 CRC 的工程细菌疗法
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-30 DOI: 10.1016/j.trecan.2024.04.001
Nicole Siguenza, Arianna Brevi, Joanna T. Zhang, Arman Pabani, Abhinav Bhushan, Moumita Das, Yousong Ding, Jeff Hasty, Pradipta Ghosh, Amir Zarrinpar
{"title":"Engineered bacterial therapeutics for detecting and treating CRC","authors":"Nicole Siguenza, Arianna Brevi, Joanna T. Zhang, Arman Pabani, Abhinav Bhushan, Moumita Das, Yousong Ding, Jeff Hasty, Pradipta Ghosh, Amir Zarrinpar","doi":"10.1016/j.trecan.2024.04.001","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.04.001","url":null,"abstract":"<p>Despite an overall decrease in occurrence, colorectal cancer (CRC) remains the third most common cause of cancer deaths in the USA. Detection of CRC is difficult in high-risk groups, including those with genetic predispositions, with disease traits, or from certain demographics. There is emerging interest in using engineered bacteria to identify early CRC development, monitor changes in the adenoma and CRC microenvironment, and prevent cancer progression. Novel genetic circuits for cancer therapeutics or functions to enhance existing treatment modalities have been tested and verified <em>in vitro</em> and <em>in vivo</em>. Inclusion of biocontainment measures would prepare strains to meet therapeutic standards. Thus, engineered bacteria present an opportunity for detection and treatment of CRC lesions in a highly sensitive and specific manner.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"4 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140839917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunometabolism of CD8+ T cell differentiation in cancer 癌症中 CD8+ T 细胞分化的免疫代谢作用
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-30 DOI: 10.1016/j.trecan.2024.03.010
Hao Shi, Sidi Chen, Hongbo Chi
{"title":"Immunometabolism of CD8+ T cell differentiation in cancer","authors":"Hao Shi, Sidi Chen, Hongbo Chi","doi":"10.1016/j.trecan.2024.03.010","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.03.010","url":null,"abstract":"<p>CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) are central mediators of tumor immunity and immunotherapies. Upon tumor antigen recognition, CTLs differentiate from naive/memory-like toward terminally exhausted populations with more limited function against tumors. Such differentiation is regulated by both immune signals, including T cell receptors (TCRs), co-stimulation, and cytokines, and metabolism-associated processes. These immune signals shape the metabolic landscape via signaling, transcriptional and post-transcriptional mechanisms, while metabolic processes in turn exert spatiotemporal effects to modulate the strength and duration of immune signaling. Here, we review the bidirectional regulation between immune signals and metabolic processes, including nutrient uptake and intracellular metabolic pathways, in shaping CTL differentiation and exhaustion. We also discuss the mechanisms underlying how specific nutrient sources and metabolite-mediated signaling events orchestrate CTL biology. Understanding how metabolic programs and their interplay with immune signals instruct CTL differentiation and exhaustion is crucial to uncover tumor–immune interactions and design novel immunotherapies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"15 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140839922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precise timing of audiovisual stimulation conquers chemobrain 精确的视听刺激时机征服化疗脑
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-21 DOI: 10.1016/j.trecan.2024.04.002
Lindsey C. Mehl, Erin M. Gibson
{"title":"Precise timing of audiovisual stimulation conquers chemobrain","authors":"Lindsey C. Mehl, Erin M. Gibson","doi":"10.1016/j.trecan.2024.04.002","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.04.002","url":null,"abstract":"<p>In a recent study, <span>Kim <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"8px\" viewbox=\"0 0 8 8\" width=\"8px\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg> utilized gamma entrainment using sensory stimuli (GENUS) to rescue cognitive impairment and glial dysregulation associated with cisplatin and methotrexate chemotherapy, specifically when applied both throughout and after chemotherapy administration. GENUS provides a time-dependent, non-invasive method for treating chemobrain, with broader implications for resolving neurodegenerative neuroinflammation.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"20 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140625809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription & copyright page 订阅和版权页面
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-09 DOI: 10.1016/s2405-8033(24)00065-7
{"title":"Subscription & copyright page","authors":"","doi":"10.1016/s2405-8033(24)00065-7","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00065-7","url":null,"abstract":"Abstract not available","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"2014 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140625758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advisory Board and Contents 咨询委员会和内容
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-09 DOI: 10.1016/s2405-8033(24)00062-1
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s2405-8033(24)00062-1","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00062-1","url":null,"abstract":"Abstract not available","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"81 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140625764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development 胃癌免疫抑制微环境异质性：对疗法开发的影响
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-09 DOI: 10.1016/j.trecan.2024.03.008
Tadahito Yasuda, Y. Alan Wang
{"title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","authors":"Tadahito Yasuda, Y. Alan Wang","doi":"10.1016/j.trecan.2024.03.008","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.03.008","url":null,"abstract":"<p>Although immunotherapy has revolutionized solid tumor treatment, durable responses in gastric cancer (GC) remain limited. The heterogeneous tumor microenvironment (TME) facilitates immune evasion, contributing to resistance to conventional and immune therapies. Recent studies have highlighted how specific TME components in GC acquire immune escape capabilities through cancer-specific factors. Understanding the underlying molecular mechanisms and targeting the immunosuppressive TME will enhance immunotherapy efficacy and patient outcomes. This review summarizes recent advances in GC TME research and explores the role of the immune-suppressive system as a context-specific determinant. We also provide insights into potential treatments beyond checkpoint inhibition.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"77 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140625638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations 不断发展的免疫检查点抑制剂的体位学和用药：皮下制剂
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-06 DOI: 10.1016/j.trecan.2024.03.006
Matthew J. Hadfield, David J. Benjamin, Jonathan Krell, Jeremy Warner, Mark P. Lythgoe
{"title":"The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations","authors":"Matthew J. Hadfield, David J. Benjamin, Jonathan Krell, Jeremy Warner, Mark P. Lythgoe","doi":"10.1016/j.trecan.2024.03.006","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.03.006","url":null,"abstract":"<p>Immune checkpoint inhibitors (ICIs) have transformed cancer care. Recently, atezolizumab gained its first global approval in a subcutaneous (SC) formulation by the UK medicines regulator, being notable as the first time an FDA- and/or European Medicines Agency (EMA)-approved ICI has been licensed via this administration route. Here, we discuss this approval, other SC ICIs in development, and the benefits and challenges of this administration route, including potential implications for patient care.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"45 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140629768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A big step for MYC-targeted therapies 向MYC靶向疗法迈出一大步
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-04-05 DOI: 10.1016/j.trecan.2024.03.009
Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher
{"title":"A big step for MYC-targeted therapies","authors":"Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher","doi":"10.1016/j.trecan.2024.03.009","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.03.009","url":null,"abstract":"<p>The <em>MYC</em> proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by <span>Garralda <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"8px\" viewbox=\"0 0 8 8\" width=\"8px\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg> of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"9 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140625754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信